Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cidara Therapeutics Files for IPO

By Drug Discovery Trends Editor | March 16, 2015

Cidara Therapeutics filed for an initial public offering (IPO) with the Securities and Exchange Commission (SEC) on Friday aiming to raise $69 million and be traded on the NASDAQ under the symbol CDTX.

The S-1 filing the biotech firm submitted breaks down what the new funds would be used for:

First, roughly $25 million will be spent on advancing the clinical development of lead candidate CD101 IV and its counterpart CD101 Topical, two drugs for treating fungal infections, which Cidara specializes in.

Another $15 million will be allocated towards bolstering the preclinical and clinical trial programs for drugs made through Cidara’s immunotherapy platform called Cloudbreak.

Cloudbreak works by manufacturing compounds “designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease,” according to the filing’s prospectus summary.

The remainder of the capital is intended for R&D efforts regarding the expansion of the Cloudbreak tool into other disease areas as well as other matters such as “general operating expenses.”

Fiercebiotech’s John Carroll reports that “the experience of the executive team,” specifically mentioning CEO Jeff Stein, may have been one of the contributing factors to the company’s plan to quickly try and join the public markets despite being only two years old.

The target date for fundraising begins at the end of the month. You can read the rest of the filing here.

Establish your company as a technology leader. For 50 years, the R&D 100 Awards, widely recognized as the “Oscars of Invention,” have showcased products of technological significance. Learn more. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE